Many Bright Ideas Technologies (OTCMKTS:MBGNF) versus Agilent Technologies (NYSE:A) Financial Contrast

Many Bright Ideas Technologies (OTCMKTS:MBGNF) and Agilent Technologies (NYSE:A) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Profitability

This table compares Many Bright Ideas Technologies and Agilent Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Many Bright Ideas Technologies	N/A	N/A	N/A
Agilent Technologies	19.55%	24.33%	12.99%

Analyst Recommendations

This is a summary of recent ratings for Many Bright Ideas Technologies and Agilent Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Many Bright Ideas Technologies	0	0	0	0	0.00
Agilent Technologies	0	4	13	2	2.89

Agilent Technologies has a consensus price target of $159.35, indicating a potential upside of 13.24%. Given Agilent Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe Agilent Technologies is more favorable than Many Bright Ideas Technologies.

Earnings & Valuation

This table compares Many Bright Ideas Technologies and Agilent Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Many Bright Ideas Technologies	N/A	N/A	N/A	N/A	N/A
Agilent Technologies	$6.95 billion	5.72	$1.30 billion	$4.98	28.26

Agilent Technologies has higher revenue and earnings than Many Bright Ideas Technologies.

Summary

Agilent Technologies beats Many Bright Ideas Technologies on 8 of the 8 factors compared between the two stocks.

About Many Bright Ideas Technologies

Many Bright Ideas Technologies Inc. does not have significant operations. It was previously engaged in the life science business with a focus on the commercialization of prognostic genomic-based tests for non-small-cell lung cancer. It focuses on the commercialization of technologies in various industrial sectors. The company is headquartered in Vancouver, Canada.

About Agilent Technologies

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer’s representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.